Industry analysts widely expect Benlysta, one the most closely watched medicines of the year, to secure the Food and Drug Administration’s blessing by Thursday.
Filed under: Noticias de Salud | Tagged: Belimumab, Food and Drug Administration, GlaxoSmithKline, Human Genome Sciences, RBC Capital Markets, Reuters, Systemic lupus erythematosus, Thomson Reuters | Leave a Comment »
